Literature DB >> 26169584

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

Todd Morgan1, Ganesh Palapattu, John Wei.   

Abstract

Urology has been beset by several major trends that have shifted the entire paradigm for prostate cancer screening. These stem from a backlash against overdiagnosis and overtreatment due to prostate-specific antigen (PSA)-based screening efforts and have led national societies to modify their guidelines. More importantly, the public outcry has shifted the focus of early detection from an effort to diagnose any and all prostate cancers to an effort to diagnose clinically significant prostate cancers at an early stage. This review provides an update on contemporary biomarkers for prostate cancer that may be used to supplement PSA-based screening approaches.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26169584     DOI： 10.1007/s11934-015-0537-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  44 in total

1.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Authors:  Jack Groskopf; Sheila M J Aubin; Ina Lim Deras; Amy Blase; Sharon Bodrug; Craig Clark; Steven Brentano; Jeannette Mathis; Jimmykim Pham; Troels Meyer; Michelle Cass; Petrea Hodge; Maria Luz Macairan; Leonard S Marks; Harry Rittenhouse
Journal:  Clin Chem       Date:  2006-04-20       Impact factor: 8.327

2.  Prostate cancer screening--the evidence, the recommendations, and the clinical implications.

Authors:  Roger Chou; Michael L LeFevre
Journal:  JAMA       Date:  2011-12-28       Impact factor: 56.272

3.  A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.

Authors:  Andrew J Vickers; Amit Gupta; Caroline J Savage; Kim Pettersson; Anders Dahlin; Anders Bjartell; Jonas Manjer; Peter T Scardino; David Ulmert; Hans Lilja
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-08       Impact factor: 4.254

Review 4.  Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen.

Authors:  R A Stephenson; J L Stanford
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

5.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

Authors:  M J Bussemakers; A van Bokhoven; G W Verhaegh; F P Smit; H F Karthaus; J A Schalken; F M Debruyne; N Ru; W B Isaacs
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

6.  The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.

Authors:  Martijn P M Q van Gils; Daphne Hessels; Onno van Hooij; Sander A Jannink; W Pim Peelen; Suzanne L J Hanssen; J Alfred Witjes; Erik B Cornel; Herbert F M Karthaus; Geert A H J Smits; Gerhard A Dijkman; Peter F A Mulders; Jack A Schalken
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

7.  Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.

Authors:  Massimo Lazzeri; Alexander Haese; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Vincenzo Scattoni; Vittorio Bini; Massimo Freschi; Amy Sussman; Bijan Ghaleh; Philippe Le Corvoisier; Josep Alberola Bou; Salvador Esquena Fernández; Markus Graefen; Giorgio Guazzoni
Journal:  Eur Urol       Date:  2013-01-24       Impact factor: 20.096

8.  The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Authors:  Moniek M Vedder; Esther W de Bekker-Grob; Hans G Lilja; Andrew J Vickers; Geert J L H van Leenders; Ewout W Steyerberg; Monique J Roobol
Journal:  Eur Urol       Date:  2014-08-26       Impact factor: 20.096

9.  The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.

Authors:  John R Prensner; Matthew K Iyer; Anirban Sahu; Irfan A Asangani; Qi Cao; Lalit Patel; Ismael A Vergara; Elai Davicioni; Nicholas Erho; Mercedeh Ghadessi; Robert B Jenkins; Timothy J Triche; Rohit Malik; Rachel Bedenis; Natalie McGregor; Teng Ma; Wei Chen; Sumin Han; Xiaojun Jing; Xuhong Cao; Xiaoju Wang; Benjamin Chandler; Wei Yan; Javed Siddiqui; Lakshmi P Kunju; Saravana M Dhanasekaran; Kenneth J Pienta; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-09-29       Impact factor: 38.330

10.  A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer.

Authors:  Rohit Mehra; Yang Shi; Aaron M Udager; John R Prensner; Anirban Sahu; Matthew K Iyer; Javed Siddiqui; Xuhong Cao; John Wei; Hui Jiang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2014-12       Impact factor: 5.715
View more
  2 in total

Review 1.  What's new in screening in 2015?

Authors:  Sigrid V Carlsson; Monique J Roobol
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

Review 2.  Biomarkers in localized prostate cancer.

Authors:  Matteo Ferro; Carlo Buonerba; Daniela Terracciano; Giuseppe Lucarelli; Vincenzo Cosimato; Danilo Bottero; Victor M Deliu; Pasquale Ditonno; Sisto Perdonà; Riccardo Autorino; Ioman Coman; Sabino De Placido; Giuseppe Di Lorenzo; Ottavio De Cobelli
Journal:  Future Oncol       Date:  2016-01-15       Impact factor: 3.404
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.